http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
선박 운항 시뮬레이터 기반 자동항해장치(Autopilot) 개선 요소 도출을 위한 사용성 평가
황훈규(Hun-Gyu Hwang),김배성(Bae-Sung Kim),유주연(Ju-Yeon Yoo),신일식(Il-Sik Sin),김정훈(Jung-Hun Kim) 한국항해항만학회 2020 한국항해항만학회 학술대회논문집 Vol.2020 No.춘계
자동항해장치는 각종 항법 센서와 연계하여 설정된 선수방위에 따라 타(rudder)를 제어하여 선박의 운항을 지원하는 장비이다. 과거의 자동항해장치는 선수방위(heading)를 유지하는 방식의 선수방위제어장치(HCS, heading control system)의 개념이었다. 하지만, 최근에는 전자해도표시장치(ECDIS, electronic chart display and information system) 등 각종 항해통신장비와 연계하여 계획된 항로를 유지하거나 적절한 시기에 변침을 해주는 항적제어장치(TCS, track control system)의 개념으로 발전되었다. 자율운항선박으로의 패러다임 전환에 대응하기 위해서는 각종 항해통신장비와 조타 및 추진 장비가 연계되어 선박을 제어하기 위한 TCS의 핵심 기술 확보가 필수적이다. 실제 국내에서는 이러한 두 가지 개념의 자동항해장치 중, HCS는 상용화 중인 상태이며 TCS로 확장하기 위한 기술은 현재 상당 부분 개발이 진행 중이다. 본 논문에서는 국내 A기업이 개발한 HCS의 개선 요소를 도출하고, TCS로 확장 시에 이를 반영하여 사용성 및 품질을 향상하기 위한 과정에 관한 내용을 다룬다. 이를 위해서는 항해사가 해당 시스템을 실제 사용해 본 후, 경험에 근거하여 불편하거나 효율적이지 않은 부분과 추가 혹은 제거되어야 하는 기능 등을 도출하기 위한 절차가 필요하다. 이러한 일련의 과정들은 실제 환경에서 진행하는 것이 가장 좋지만, 이는 선교 설치 및 타 장비와의 연동 문제, 혹시 모를 안전상의 문제 등 여러 제약이 따르기 때문에 본 논문에서는 선박 운항 시뮬레이터(FMSS, full mission ship-handling simulator)와의 연계를 통해 HCS의 개선 요소 도출을 위한 평가를 수행하는 것에 관한 내용을 다룬다.
Is the Impedance Baseline Helpful in the Evaluation of Globus Patients?
( Yeon Joo Chun ),( Myung Gyu Choi ),( Hyung Hun Kim ),( Yu Kyung Cho ),( Aekyeong Ku ) 대한소화기기능성질환·운동학회 2015 Journal of Neurogastroenterology and Motility (JNM Vol.21 No.3
Background/Aims: Gastroesophageal reflux disease (GERD) has been suggested to be responsible for 23-68% of globus cases. The impedance baseline (IB) acquired by 24-hour multichannel intraluminal impedance monitoring has been proven to represent esophageal mucosal integrity. We aimed to investigate whether the IB is helpful for evaluating globus patients. Methods: Twenty-four-hour multichannel intraluminal impedance pH tracings (MII-pH) were evaluated in globus patients. Differences in the IB between the acid reflux, non-acid reflux, and no reflux groups were analyzed. Receiver operating characteristic (ROC) curves were obtained to determine the optimal measurement point from the lower esophageal sphincter (LES). Results: A total of 62 patients were analyzed. MII-pH showed that acid reflux, non-acid reflux, and no reflux were present in 13, 5, and 44 patients, respectively. The acid reflux group had a significantly lower IB than the other groups at a location 3 cm from the LES. ROC curve analysis revealed that placement at a position 3 cm from the LES resulted in moderate diagnostic accuracy (area under the curve = 0.88). When we set 2500 Ω as the cut-off value for acid reflux at a position 3 cm from the LES, the additional diagnostic yield for acid reflux was increased by 19.4% compared with that obtained by MII-pH. Conclusions: IB is complementary to pH findings enabling identification of a subset of patients with co-existing acid reflux. Catheter placement at a location 3 cm from the LES and a cut-off value of 2500 Ω may be reasonable criteria for estimating acid reflux. (J Neurogastroenterol Motil 2015;21:390-397)
Are There Hopeful Therapeutic Strategies to Regenerate the Infarcted Hearts?
Gyu-Chul Oh,Yeon-Jik Choi,Bong-Woo Park,Kiwon Ban,Hun-Jun Park The Korean Society of Cardiology 2023 Korean Circulation Journal Vol.53 No.6
Ischemic heart disease remains the primary cause of morbidity and mortality worldwide. Despite significant advancements in pharmacological and revascularization techniques in the late 20th century, heart failure prevalence after myocardial infarction has gradually increased over the last 2 decades. After ischemic injury, pathological remodeling results in cardiomyocytes (CMs) loss and fibrosis, which leads to impaired heart function. Unfortunately, there are no clinical therapies to regenerate CMs to date, and the adult heart's limited turnover rate of CMs hinders its ability to self-regenerate. In this review, we present novel therapeutic strategies to regenerate injured myocardium, including (1) reconstruction of cardiac niche microenvironment, (2) recruitment of functional CMs by promoting their proliferation or differentiation, and (3) organizing 3-dimensional tissue construct beyond the CMs. Additionally, we highlight recent mechanistic insights that govern these strategies and identify current challenges in translating these approaches to human patients.
Seo-Yeon Ahn,Sang Kyun Son,Gyu Hyung Lee,Inho Kim,June-Won Cheong,Won Sik Lee,Byung Soo Kim,Deog-Yeon Jo,Chul Won Jung,Chu Myoung Seong,Jae Hoon Lee,Young Jin Yuh,Min Kyoung Kim,Hun-Mo Ryoo,Moo-Rim Pa 대한혈액학회 2022 Blood Research Vol.57 No.2
Background Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This study aimed to confirm the safety and efficacy of nilotinib in routine clinical practice within South Korea. Methods An open-label, multicenter, single-arm, 12-week observational post-marketing surveillance (PMS) study was conducted on 669 Korean adult patients with Ph+ CML from December 24, 2010, to December 23, 2016. The patients received nilotinib treatment in routine clinical practice settings. Safety was evaluated by all types of adverse events (AEs) during the study period, and efficacy was evaluated by the complete hematological response (CHR) and cytogenetic response. Results During the study period, AEs occurred in 61.3% (410 patients, 973 events), adverse drug reactions (ADRs) in 40.5% (271/669 patients, 559 events), serious AEs in 4.5% (30 patients, 37 events), and serious ADRs in 0.7% (5 patients, 8 events). Furthermore, unexpected AEs occurred at a rate of 6.9% (46 patients, 55 events) and unexpected ADRs at 1.2% (8 patients, 8 events). As for the efficacy results, CHR was achieved in 89.5% (442/494 patients), and minor cytogenetic response or major cytogenetic response was achieved in 85.8% (139/162 patients). Conclusion This PMS study shows consistent results in terms of safety and efficacy compared with previous studies. Nilotinib was well tolerated and efficacious in adult Korean patients with Ph+ CML in routine clinical practice settings.
( Hyun Gyu Choi ),( Yeon Ho Choi ),( Ji Hyang Kim ),( Hui Hun Kim ),( Sang Hyun Kim ),( Jeong Ah Kim ),( Sang Myung Lee ),( Minkyun Na ),( Seung Ho Lee ) 영남대학교 약품개발연구소 2014 영남대학교 약품개발연구소 연구업적집 Vol.24 No.0
A new neolignan, linderin A (1), together with six known lignans, (+)-xanthoxyol (2), pluviatilol (3), actiforin (4), (+)-syringaresinol (5), (+)-(7S,8R,8`R)-acuminatolide (6), and (+)-9`-O-trans-feruloyl-5,5`-dimethoxylariciresinol (7) were isolated from the stems of Lindera obtusiloba Blume (Lauraceae). Their chemical structures were elucidated by a combination of spectroscopic analysis and chemical reaction, and the absolute configuration of 1 was determined by Mosher`s esterification. The effect of compounds 1-7 on tumor necrosis factor (TNF)-α, interleukin(IL)-6, and their inhibitory activity of histamine release were examined using human mast cells. Among the lignans tested, compounds 1, 3, 4, 6, and 7 inhibited release of histamine from mast cells. Especially, compounds 1 and 4 suppressed the gene expressions of pro-inflammatory cytokines, TNF-α, and IL-6 in human mast cells. Our findings suggest that the lignan constituents in L. obtusiloba may contribute to its anti-allergic inflammatory effects.